- Home
- PHAT vs EVMN Comparison
PHAT vs EVMN Comparison
Compare PHAT & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAT | EVMN |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United States |
| Employees | N/A | 48 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 894.0M | 825.5M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PHAT | EVMN |
|---|---|---|
| Price | $11.47 | $21.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $19.83 | ★ $43.88 |
| AVG Volume (30 Days) | ★ 1.4M | 304.1K |
| Earning Date | 04-30-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $175,110,000.00 | N/A |
| Revenue This Year | $93.04 | N/A |
| Revenue Next Year | $58.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $3.69 | $13.89 |
| 52 Week High | $18.31 | $33.20 |
Technical Indicators
Market Signals| Indicator | PHAT | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 43.56 | 36.33 |
| Support Level | $11.27 | $21.39 |
| Resistance Level | $11.54 | $23.08 |
| Average True Range (ATR) | 0.91 | 1.49 |
| MACD | -0.12 | -0.25 |
| Stochastic Oscillator | 45.01 | 8.30 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.